Duvalizumab is a selective and high-affinity monoclonal antibody against human immunoglobulin G1K that completes the process of T-cell recognition and tumor cell killing by blocking the binding of PD-L1 to PD-1 and CD80 [133]. This evidence concerns the gene CD274 and neoplasm.